Basis: FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/B ratio high or low?
The P/B ratio of 1.12 is 55% below its estimated 1-year average of 2.46, near the low end of its estimated 1-year range (1.12–3.07).
As of 2026-10-06T14:16:33.039Z.
Calculation as of: 2026-10-06T14:16:33.039Z.
Quote observation: 2026-10-06T14:15:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5811ce025d9976e80ea69b9f8bae613fc78d61205a97c72640e2bc4d521a59ba
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PB RATIO
1.12
PB RATIO AVG TTM
N/A
PB RATIO AVG 3Y
N/A
PB RATIO AVG 5Y
N/A
PB RATIO AVG 10Y
N/A
PB RATIO AVG 15Y
N/A
PB RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.46
median of 504 covered companies
CURRENT VS SECTOR MEDIAN
-54.56%
vs the sector median at left
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | $52.05M | 1.12 | N/A | N/A | N/A |
| Envoy Medical, Inc. (COCH)vs › | $51.72M | 15.66 | 11.51 | 9.36 | 5.08 |
| INmune Bio, Inc. (INMB)vs › | $51.31M | 2.52 | 1.94 | 3.26 | 2.92 |
| biote Corp. (BTMD)vs › | $50.28M | N/A | 18.22 | 18.22 | 18.22 |
| Microbot Medical Inc. (MBOT)vs › | $50.13M | 0.73 | 1.70 | 2.98 | 3.06 |
| ImageneBio Inc (IMA)vs › | $53.01M | 0.37 | 0.45 | 0.40 | 0.73 |
| Clene Inc. (CLNN)vs › | $49.52M | N/A | 4.45 | 27.22 | 162.33 |
| Celularity Inc. (CELU)vs › | $49.49M | N/A | 3.45 | 2.03 | 2.35 |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $54.14M | 0.79 | 0.72 | 1.87 | 2.54 |
| Lite Strategy, Inc. (LITS)vs › | $47.01M | 1.13 | 0.31 | 0.37 | 0.37 |
At 1.12, P/B is below its estimated 1-year median — higher than 0% of readings in its estimated 1-year history.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
estimated 1-year low
2.08
median
2.40
estimated 1-year high
3.07
P/B Ratio
1.12
Market Price / Book Value per Share
PB Ratio = Market Cap / (Total Shareholders' Equity − Preferred Stock)
The price-to-book ratio compares market capitalization to book value attributable to common shareholders (total equity minus preferred stock). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PB RATIO |
|---|---|
| 2026-10-05 | 2.25 |
| 2026-10-02 | 2.27 |
| 2026-10-01 | 2.30 |
| 2026-09-30 | 2.24 |
| 2026-09-29 | 2.26 |
| 2026-09-28 | 2.19 |
| 2026-09-25 | 2.20 |
| 2026-09-24 | 2.34 |
| 2026-09-23 | 2.26 |
| 2026-09-22 | 2.45 |
| 2026-09-21 | 2.51 |
| 2026-09-18 | 2.55 |
| 2026-09-17 | 2.57 |
| 2026-09-16 | 2.58 |
| 2026-09-15 | 2.67 |
| 2026-09-14 | 2.38 |
| 2026-09-11 | 2.30 |
| 2026-09-10 | 2.38 |
| 2026-09-09 | 2.42 |
| 2026-09-08 | 2.36 |
| 2026-09-04 | 2.19 |
| 2026-09-03 | 2.08 |
| 2026-09-02 | 2.32 |
| 2026-09-01 | 2.20 |
| 2026-08-31 | 2.45 |
| 2026-08-28 | 2.20 |
| 2026-08-27 | 2.34 |
| 2026-08-26 | 2.71 |
| 2026-08-25 | 2.82 |
| 2026-08-24 | 2.92 |
| 2026-08-21 | 3.07 |
| 2026-08-20 | 2.64 |
| 2026-08-19 | 2.66 |
| 2026-08-18 | 2.67 |
| 2026-08-17 | 2.70 |
| 2026-08-14 | 2.74 |
| 2026-08-13 | 2.79 |
| 2026-08-12 | 2.67 |